Abstract: Lentiviral vector (LV) formulations, and pharmaceutical compositions comprising such LV formulations, with improved stability and suitable for systemic administration are provided. Methods for treating disorders, especially blood disorders, using systemic administration of LV formulations are also provided.

Abstract: Compositions and methods including a bioactive compound and a triazine compound comprising: formula (I) or formula (II) and proton tautomers and salts thereof . Each R2 is independently selected from any electron donating group, electron withdrawing group and electron neutral group. R3 is selected from the group consisting of substituted heteroaromatic rings, unsubstituted heteroaromatic rings, substituted heterocyclic rings, and unsubstituted heterocyclic rings, that are linked to the triazine group through a nitrogen atom within a ring of R3.

Abstract: A device includes a substrate having first and second major surfaces and a hub that defines an axis of rotation for the substrate, and an unvented channel having a plurality of connected compartments. Methods for using devices of the invention are also disclosed.